In an interview with CancerNetwork®, Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, discussed the use of autologous stem cell transplant in patients with relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL) during the era of CAR T-cell therapy.
In a data analysis using the Center of International Bone Marrow Transplant Registry (CI-BMTR), Shah and fellow investigators evaluated whether the use of autologous transplantation in this patient population should remain the standard of care.
The results of the analysis, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, strongly supported that autologous transplantation should remain the current standard of care.
Transcription:
Yes, I think the most important finding that I take away from this is that until we have randomized controlled trial data that shows that CAR…
